» Articles » PMID: 33212921

Microneedles Drug Delivery Systems for Treatment of Cancer: A Recent Update

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2020 Nov 20
PMID 33212921
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Microneedles (MNs) are tiny needle like structures used in drug delivery through layers of the skin. They are non-invasive and are associated with significantly less or no pain at the site of administration to the skin. MNs are excellent in delivering both small and large molecules to the subjects in need thereof. There exist several strategies for drug delivery using MNs, wherein each strategy has its pros and cons. Research in this domain lead to product development and commercialization for clinical use. Additionally, several MN-based products are undergoing clinical trials to evaluate its safety, efficacy, and tolerability. The present review begins by providing bird's-eye view about the general characteristics of MNs followed by providing recent updates in the treatment of cancer using MNs. Particularly, we provide an overview of various aspects namely: anti-cancerous MNs that work based on sensor technology, MNs for treatment of breast cancer, skin carcinoma, prostate cancer, and MNs fabricated by additive manufacturing or 3 dimensional printing for treatment of cancer. Further, the review also provides limitations, safety concerns, and latest updates about the clinical trials on MNs for the treatment of cancer. Furthermore, we also provide a regulatory overview from the "United States Food and Drug Administration" about MNs.

Citing Articles

Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.

Andrew J, Ezra-Manicum A, Witika B EJNMMI Radiopharm Chem. 2024; 9(1):62.

PMID: 39180599 PMC: 11344754. DOI: 10.1186/s41181-024-00295-7.


Advances in Polysaccharide-Based Microneedle Systems for the Treatment of Ocular Diseases.

Bao Q, Zhang X, Hao Z, Li Q, Wu F, Wang K Nanomicro Lett. 2024; 16(1):268.

PMID: 39136800 PMC: 11322514. DOI: 10.1007/s40820-024-01477-3.


Microneedles for Efficient and Precise Drug Delivery in Cancer Therapy.

Ganeson K, Alias A, Murugaiyah V, Amirul A, Ramakrishna S, Vigneswari S Pharmaceutics. 2023; 15(3).

PMID: 36986606 PMC: 10057903. DOI: 10.3390/pharmaceutics15030744.


Application of Convergent Science and Technology toward Ocular Disease Treatment.

Bal-Ozturk A, Ozcan-Bulbul E, Gultekin H, Cecen B, Demir E, Zarepour A Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986546 PMC: 10053244. DOI: 10.3390/ph16030445.


Revolutionizing Therapeutic Delivery with Microneedle Technology for Tumor Treatment.

Desai V, Priya S, Gorantla S, Singhvi G Pharmaceutics. 2023; 15(1).

PMID: 36678643 PMC: 9866211. DOI: 10.3390/pharmaceutics15010014.


References
1.
Kardjito T, Donosepoetro M, Grange J . The Mantoux test in tuberculosis: correlations between the diameters of the dermal responses and the serum protein levels. Tubercle. 1981; 62(1):31-5. DOI: 10.1016/0041-3879(81)90032-5. View

2.
Takeuchi K, Kim B . Functionalized microneedles for continuous glucose monitoring. Nano Converg. 2018; 5(1):28. PMC: 6199201. DOI: 10.1186/s40580-018-0161-2. View

3.
Nam J, Son S, Ochyl L, Kuai R, Schwendeman A, Moon J . Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018; 9(1):1074. PMC: 5852008. DOI: 10.1038/s41467-018-03473-9. View

4.
Simoes M, Sousa J, Pais A . Skin cancer and new treatment perspectives: a review. Cancer Lett. 2014; 357(1):8-42. DOI: 10.1016/j.canlet.2014.11.001. View

5.
Vemulapalli V, Yang Y, Friden P, Banga A . Synergistic effect of iontophoresis and soluble microneedles for transdermal delivery of methotrexate. J Pharm Pharmacol. 2007; 60(1):27-33. DOI: 10.1211/jpp.60.1.0004. View